Search
for
Sort by
Research 30 of 534
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from Centipeda minima
- Under Development JAK Inhibitors for Dermatologic Diseases
- Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- JAK inhibitors in dermatology: The promise of a new drug class
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
- Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- Molecular Predictors of Ritlecitinib Efficacy in Alopecia Areata: Role of JAK3-Dependent Inflammation and Follicular Integrity
- 0935 Unravelling the role of JAK3/TEC kinase signalling with ritlecitinib in alopecia areata lesional skin and alopecia areata-induced human hair follicles ex vivo
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Janus Kinase inhibitors in dermatology: a review
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo
- Small Molecule Inhibitors and Inflammatory Skin Diseases